Skip to main content
SpringerLink
Log in
Book cover

Mohs Micrographic Surgery pp 211–223Cite as

Mohs Micrographic Surgery for the Treatment of Cutaneous Melanoma

  • Chapter
  • First Online:

  • 1884 Accesses

Abstract

Melanoma is a clinically and biologically diverse malignancy for which complete surgical excision offers the only chance for cure. Current guidelines for surgical excision margins are based on consensus recommendations, and clear, evidence-based data to guide the surgeon in each case is limited. Mohs micrographic surgery (MMS) offers the surgeon the ability to assess 100% of the surgical margin, far better than margins evaluated with the standard bread-loaf sectioning technique. Immunohistochemical stains such as MART-1 allow for the reliable identification of melanoma in frozen sections and produce cure rates at least as good as standard excision with traditional margins.

*Both authors contributed equally to the manuscript.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol. 2009;20 Suppl 6:1–7.

    Google Scholar 

  2. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin. 2010;60:301–16.

    Article  PubMed  Google Scholar 

  3. Terando A, Sabel MS, Sondak VK. Melanoma: adjuvant therapy and other treatment options. Curr Treat Options Oncol. 2003;4:187–99.

    Article  PubMed  Google Scholar 

  4. Crosby T, Mason M, Savage P. Malignant melanoma (non-metastatic). Clin Evid. 2005;14:2058–72.

    PubMed  Google Scholar 

  5. Cooper JS. Radiation therapy of malignant melanoma. Dermatol Clin. 2002;20:713–6.

    Article  PubMed  Google Scholar 

  6. Cascinelli N, Santinami M, Maurichi A, Patuzzo R, Pennacchioli E. World Health Organization experience in the treatment of melanoma. Surg Clin North Am. 2003;83:405–16.

    Article  PubMed  Google Scholar 

  7. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22:3138–51.

    Article  PubMed  CAS  Google Scholar 

  8. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596–9.

    Article  PubMed  CAS  Google Scholar 

  9. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010;22:178–83.

    Article  PubMed  CAS  Google Scholar 

  10. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.

    Article  PubMed  CAS  Google Scholar 

  11. Campoli M, Ferrone S. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? Expert Rev Vaccines. 2004;3:171–87.

    Article  PubMed  CAS  Google Scholar 

  12. Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther. 2009;9:1583–98.

    Article  PubMed  CAS  Google Scholar 

  13. Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res. 2009;22:711–23.

    Article  PubMed  CAS  Google Scholar 

  14. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res. 2010;16:11–20.

    Article  PubMed  CAS  Google Scholar 

  15. Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin’s lymphoma. Expert Opin Biol Ther. 2010;10:807–17.

    Article  PubMed  CAS  Google Scholar 

  16. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol. 2010;74:27–39.

    Article  PubMed  Google Scholar 

  17. Morton DL. Current management of malignant melanoma. Ann Surg. 1990;212:123–4.

    Article  PubMed  CAS  Google Scholar 

  18. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas 1–4 mm. Ann Surg. 1993;218:262–9.

    Article  PubMed  CAS  Google Scholar 

  19. Breslow A, Macht SD. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet. 1997;145:691–2.

    Google Scholar 

  20. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4 cm) primary melanoma. Ann Surg Oncol. 1998;5:322–8.

    Article  PubMed  CAS  Google Scholar 

  21. Clark Jr WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–27.

    PubMed  Google Scholar 

  22. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–8.

    Article  PubMed  CAS  Google Scholar 

  23. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159–62.

    Article  PubMed  CAS  Google Scholar 

  24. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol. 1998;14:272–5.

    Article  PubMed  CAS  Google Scholar 

  25. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer. 2000;89:1495–501.

    Article  PubMed  CAS  Google Scholar 

  26. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol. 2001;8:101–8.

    PubMed  CAS  Google Scholar 

  27. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97:1941–6.

    Article  PubMed  Google Scholar 

  28. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–66.

    Article  PubMed  CAS  Google Scholar 

  29. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009;4:CD004835.

    PubMed  Google Scholar 

  30. Leiter U, Eigentler TK, Forschner A, et al. Excision guidelines and follow-up strategies in cutaneous melanoma: facts and controversies. Clin Dermatol. 2010;28:311–5.

    Article  PubMed  Google Scholar 

  31. Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Insa A, Fortea JM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res. 2005;15:169–77.

    Article  PubMed  Google Scholar 

  32. Day Jr CL, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194:108–12.

    Article  PubMed  Google Scholar 

  33. Day Jr CL, Mihm Jr MC, Lew RA, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg. 1982;195:35–43.

    Article  PubMed  Google Scholar 

  34. Harrist TJ, Rigel DS, Day Jr CL, et al. Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer. 1984;53:2183–7.

    Article  PubMed  CAS  Google Scholar 

  35. León P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark Jr WH. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg. 1991;126:1461–8.

    Article  PubMed  Google Scholar 

  36. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller 3rd JR, Leong SP. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134:983–7.

    Article  PubMed  CAS  Google Scholar 

  37. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    Article  PubMed  Google Scholar 

  38. Macht SD. Depth of excision of melanomas. JAMA. 2001;286:167–8.

    Article  PubMed  CAS  Google Scholar 

  39. Wolf Y, Balicer RD, Amir A, Feinmesser M, Hauben DJ. The vertical dimension in the surgical treatment of cutaneous malignant melanoma – how deep is deep? Eur J Plast Surg. 2001;24:74–7.

    Article  Google Scholar 

  40. Charles CA, Yee VS, Dusza SW, et al. Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists. Arch Dermatol. 2005;141:723–9.

    Article  PubMed  Google Scholar 

  41. NIH consensus conference: diagnosis and treatment of early melanoma. JAMA. 1992;268:1314–9.

    Google Scholar 

  42. Coit DG, Andtbacka R, Bichakjian CK, NCCN Melanoma Panel, et al. Melanoma. J Natl Compr Canc Netw. 2009;7:250–75.

    PubMed  CAS  Google Scholar 

  43. Roberts DLL, Anstey AV, Barlow RJ, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7–17.

    Article  PubMed  CAS  Google Scholar 

  44. Sober AJ, Chuang TY, Duvic M, Guidelines/Outcomes Committee, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45:579–86.

    Article  PubMed  CAS  Google Scholar 

  45. Johnson TM, Sondak VK. A centimeter here, a centimeter there: does it matter? J Am Acad Dermatol. 1995;33:532–4.

    Article  PubMed  CAS  Google Scholar 

  46. Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:92–100.

    Article  PubMed  Google Scholar 

  47. Urist MM, Balch CM, Soong SJ, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer. 1985;55:1398–402.

    Article  PubMed  CAS  Google Scholar 

  48. O’Brien CJ, Coates AS, Peterson-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162:310–4.

    Article  PubMed  Google Scholar 

  49. Anderson AP, Gottlieb J, Drzewlecki KT, Hou-Jensen K, Sondergaard K. Skin melanoma of the head and neck. Prognostic factors and recurrence-free survival in 512 patients. Cancer. 1992;69:1153–6.

    Article  Google Scholar 

  50. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg. 1995;21:285–90.

    Article  PubMed  CAS  Google Scholar 

  51. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996;3:446–52.

    Article  PubMed  CAS  Google Scholar 

  52. Furukawa H, Tsutsumida A, Yamamoto Y, et al. Melanoma of thumb: retrospective study for amputation levels, surgical margin and reconstruction. J Plast Reconstr Aesthet Surg. 2007;60:24–31.

    Article  PubMed  Google Scholar 

  53. Cohen T, Busam KJ, Patel A, Brady MS. Subungual melanoma: management considerations. Am J Surg. 2008;195:244–8.

    Article  PubMed  Google Scholar 

  54. Kimyai-Asadi A, Katz T, Goldberg LH, et al. Margin involvement after the excision of melanoma in situ: the need for complete en face examination of the surgical margins. Dermatol Surg. 2007;33:1434–9.

    PubMed  CAS  Google Scholar 

  55. Debloom JR, Zitelli JA, Brodland DG. The invasive growth potential of residual melanoma and melanoma in situ. Dermatol Surg. 2010;36:1251–7.

    Article  PubMed  CAS  Google Scholar 

  56. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123:340–4.

    Article  PubMed  CAS  Google Scholar 

  57. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241–8.

    Article  PubMed  CAS  Google Scholar 

  58. Parker TL, Zitelli JA. Surgical margins for excision of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1995;32:233–6.

    Article  PubMed  CAS  Google Scholar 

  59. Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev. 2008;34:728–36.

    Article  PubMed  CAS  Google Scholar 

  60. Mohs FE. Chemosurgery for melanoma. Arch Dermatol. 1977;113:285–91.

    Article  PubMed  CAS  Google Scholar 

  61. Mohs FE. Chemosurgery: microscopically controlled surgery for skin cancer. Springfield: Charles C Thomas; 1978. p. 225–48.

    Google Scholar 

  62. Mohs FE. Microscopically controlled surgery for periorbital melanoma: fixed-tissue and fresh-tissue techniques. J Dermatol Surg Oncol. 1985;11:284–91.

    PubMed  CAS  Google Scholar 

  63. Fewkes J, Mohs FE. Microscopically controlled surgical excision (the Mohs technique). In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general medicine. New York: McGraw-Hill; 1987. p. 2557–63.

    Google Scholar 

  64. Mohs FE. Fixed tissue micrographic surgery for melanoma of the ear. Arch Otolaryngol Head Neck Surg. 1988;114:625–31.

    Article  PubMed  CAS  Google Scholar 

  65. Zitelli JA, Mohs FE, Larson P, Snow S. Mohs micrographic surgery for melanoma. Dermatol Clin. 1989;7:833–43.

    PubMed  CAS  Google Scholar 

  66. Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37:236–45.

    Article  PubMed  CAS  Google Scholar 

  67. Cohen LM, McCall MW, Hodge SJ, Freedman JD, Callen JP, Zax RH. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs micrographic surgery aided by rush permanent sections. Cancer. 1994;73:2964–70.

    Article  PubMed  CAS  Google Scholar 

  68. Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994;31:79–85.

    Article  PubMed  CAS  Google Scholar 

  69. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg. 1998;24:673–7.

    Article  PubMed  CAS  Google Scholar 

  70. Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg. 2003;7:25–30.

    Article  PubMed  Google Scholar 

  71. Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94:287–92.

    Article  PubMed  Google Scholar 

  72. Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol. 1991;24:102–6.

    Article  PubMed  CAS  Google Scholar 

  73. Ferrciro JA, Meyers JL, Bostwick DG. Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester. Mayo Clin Proc. 1995;70:1137–41.

    Article  Google Scholar 

  74. Snow SN, Mohs FE, Oriba HA, Dudley CM, Leverson G, Hetzer M. Cutaneous malignant melanoma treated by Mohs surgery: review of the treatment results of 179 cases from the Mohs Melanoma Registry. Dermatol Surg. 1997;23:1055–60.

    Article  PubMed  CAS  Google Scholar 

  75. Dabbs DJ. Diagnostic immunohistochemistry. Philadelphia: Churchill Livingstone; 2002.

    Google Scholar 

  76. Zalla MJ, Lim KK, Dicaudo KK, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26:771–84.

    Article  PubMed  CAS  Google Scholar 

  77. Albertini JG, Elston DM, Libow LF, Smith SB, Farley MF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg. 2002;28:656–65.

    Article  PubMed  Google Scholar 

  78. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002;46:78–84.

    Article  PubMed  Google Scholar 

  79. Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004;30:403–8.

    Article  PubMed  Google Scholar 

  80. Davis DA, Kurtz KA, Robinson RA. Ultrarapid staining for cutaneous melanoma: study and protocol. Dermatol Surg. 2005;31:753–6.

    Article  PubMed  CAS  Google Scholar 

  81. Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg. 2006;32:690–6.

    Article  PubMed  CAS  Google Scholar 

  82. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-Melan-A monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595–602.

    Article  PubMed  CAS  Google Scholar 

  83. Kaufmann O, Koch S, Burghardt J, Audring H, Dietel M. Tyrosinase, Melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740–6.

    PubMed  CAS  Google Scholar 

  84. Busam K, Jungbluth A. The new melanoma markers: MART- 1 and Melan-A (the NIH experience): author’s response. Am J Surg Pathol. 1999;23:610–3.

    Article  Google Scholar 

  85. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: MART-1 and Melan-A (the NIH experience). Am J Surg Pathol. 1999;23:607–10.

    Article  PubMed  CAS  Google Scholar 

  86. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies Melan-A, tyrosinase and HMB45 with NKIC3 and S100 protein in the evaluation of benign nevi and malignant melanoma. Histochem J. 2000;32:475–81.

    Article  PubMed  CAS  Google Scholar 

  87. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196–200.

    Article  PubMed  CAS  Google Scholar 

  88. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205–11.

    Article  PubMed  CAS  Google Scholar 

  89. Granter SR, Weilbaecher KN, Quigley C, Fisher DE. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol. 2002;10:47–51.

    Article  PubMed  Google Scholar 

  90. Sundram U, Harvell JD, Rouse RV, Natkunam Y. Expression of the B-Cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16:802–20.

    Article  PubMed  Google Scholar 

  91. Zubovits J, Buzney E, Yu L, Duncan LM. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol. 2004;35:217–23.

    Article  PubMed  CAS  Google Scholar 

  92. Hornick JL, Fletcher CDM. PEComa: what do we know so far? Histopathology. 2006;48:75–82.

    Article  PubMed  CAS  Google Scholar 

  93. Mai KT, Belanger EC. Perivascular epithelioid cell tumour (PEComa) of the soft tissue. Pathology. 2006;38:415–20.

    Article  PubMed  Google Scholar 

  94. Dim DC, Cooley LD, Miranda RN. Clear cell sarcoma of tendons and aponeuroses: a review. Arch Pathol Lab Med. 2007;131:152–6.

    PubMed  CAS  Google Scholar 

  95. Ordonez NG, Xiaolong J, Hickey RC. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol. 1988;90:385–90.

    PubMed  CAS  Google Scholar 

  96. Wick MR, Swanson PE, Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol. 1988;15:201–7.

    Article  PubMed  CAS  Google Scholar 

  97. Swanson PE, Wick MR. Clear cell sarcoma: an immunohistochemical analysis of six cases and comparison with other epithelioid neoplasms of soft tissue. Arch Pathol Lab Med. 1989;113:55–60.

    PubMed  CAS  Google Scholar 

  98. Unger PD, Hoffman K, Thung SN, Pertsemlides D, Wolfe D, Kaneko M. HMB-45 reactivity in adrenal pheochromocytomas. Arch Pathol Lab Med. 1992;116:151–3.

    PubMed  CAS  Google Scholar 

  99. Bishop PW, Menasce LP, Yates AJ, Win NA, Banerjee SS. An immunophenotypic survey of malignant melanomas. Histopathology. 1993;23:159–66.

    Article  PubMed  CAS  Google Scholar 

  100. Trefzer U, Rietz N, Chen Y, et al. SM5–1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res. 2000;292:583–9.

    Article  PubMed  CAS  Google Scholar 

  101. Deavers MT, Malpica A, Ordonez NG, Silva EG. Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol Pathol. 2003;22:162–7.

    Article  PubMed  Google Scholar 

  102. Turhan T, Oner K, Yurtseven T, Akalin T, Ovul I. Spinal meningeal melanocytoma. Report of two cases and review of the literature. J Neurosurg. 2004;100:287–90.

    Article  PubMed  Google Scholar 

  103. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230–40.

    Article  PubMed  Google Scholar 

  104. McKee PH, Calonje E, Granter SR. Pathology of the skin with clinical correlations. 3rd ed. Philadelphia: Elsevier Mosby; 2005.

    Google Scholar 

  105. O’Brien DF, Crooks D, Mallucci C, et al. Meningeal melanocytoma. Childs Nerv Syst. 2006;22:556–61.

    Article  PubMed  Google Scholar 

  106. Hofbauer GFL, Kamarashev J, Geertsen R, Boni R, Dummer R. Tyrosinase immunoreactivity in formalin-fixed, paraffin- embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998;25:204–9.

    Article  PubMed  CAS  Google Scholar 

  107. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol. 2000;182:323–31.

    Article  PubMed  CAS  Google Scholar 

  108. Busam KJ, Iversen K, Coplan KC, Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25:197–204.

    Article  PubMed  CAS  Google Scholar 

  109. King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE. Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol. 1999;155:731–8.

    Article  PubMed  CAS  Google Scholar 

  110. King R, Googe PB, Weilbacher KN, Mihm Jr MC, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;25:51–7.

    Article  PubMed  CAS  Google Scholar 

  111. Makhlouf HR, Ishak KG, Shekar R, Sesterhenn IA, Young DY, Fanburg-Smith JC. Melanoma markers in angiomyolipoma of the liver and kidney. Arch Pathol Lab Med. 2002;126:49–55.

    PubMed  Google Scholar 

  112. Salazar-Onfray F, López M, Lundqvist A, et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer. 2002;87:414–22.

    Article  PubMed  CAS  Google Scholar 

  113. Trefzer U, Chen Y, Herberth G, et al. The monoclonal antibody SM5–1 recognizes a fibronectin variant which is widely expressed in melanoma. BMC Cancer. 2006;6:8.

    Article  PubMed  CAS  Google Scholar 

  114. Reinke S, Königer P, Herberth G, et al. Differential expression of MART-1, tyrosinase, and SM5–1 in primary and metastatic melanoma. Am J Dermatopathol. 2005;27:401–16.

    Article  PubMed  Google Scholar 

  115. Busam KJ, Kucukgol D, Sato E, Frosina D, Teruya-Feldstein J, Jungbluth AA. Immunohistochemical analysis of novel mono-clonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol. 2005;29:400–6.

    Article  PubMed  Google Scholar 

  116. Roma AA, Magi-Galluzzi C, Zhou M. Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas. Arch Pathol Lab Med. 2007;131:122–5.

    PubMed  Google Scholar 

  117. Morris LG, Wen YH, Nonaka D, et al. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008;30:771–5.

    Article  PubMed  Google Scholar 

  118. Meije CB, Swart GW, Lepoole C, Das PK, Van den Oord JJ. Antigenic profiles of individual-matched pairs of primary and melanoma metastases. Hum Pathol. 2009;40:1399–407.

    Article  PubMed  CAS  Google Scholar 

  119. Mitra D, Fisher DE. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am. 2009;23:447–65.

    Article  PubMed  Google Scholar 

  120. Glass LF, Raziano RM, Clark GS, et al. Rapid frozen section immunostaining of melanocytes by microphthalmia-associated transcription factor. Am J Dermatopathol. 2010;32:319–25.

    PubMed  Google Scholar 

  121. Fernando SS, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology. 1994;26:16–9.

    Article  PubMed  CAS  Google Scholar 

  122. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res. 2010;109:73–121.

    Article  PubMed  CAS  Google Scholar 

  123. McCready DR, Ghazarian DM, Hershkop MS, Walker JA, Ambus U, Quirt IC. Sentinel lymph-node biopsy after previous wide local excision for melanoma. Can J Surg. 2001;44:432–4.

    PubMed  CAS  Google Scholar 

  124. Leong WL, Ghazarian DM, McCready DR. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity. J Surg Oncol. 2003;82:143–6.

    Article  PubMed  Google Scholar 

  125. Gannon CJ, Rousseau Jr DL, Ross MI, Johnson MM, Lee JE, Mansfield PF, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107:2647–52.

    Article  PubMed  Google Scholar 

  126. Wheeland RG, Ratz JL, Bailin PL. Mohs micrographic surgery technique. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery: principles and practice. New York: Marcel Dekker; 1997. p. 731–44.

    Google Scholar 

  127. Hendi A, Brodland DG, Zitelli JA. Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch Dermatol. 2006;142:871–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fellows, Zitelli & Brodland, P.C., Pittsburgh, PA, USA

    Michael Campoli, Scott Freeman & John Zitelli

  2. Departments of Dermatology and Otolaryngology, Shadyside Medical Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    David G. Brodland

Authors
  1. Michael Campoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David G. Brodland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Zitelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Miller School of Medicine, Dept. Dermatology, University of Miami, NW. 10th Ave. 1600, Miami, 33136, Florida, USA

    Keyvan Nouri

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag London Limited

About this chapter

Cite this chapter

Campoli, M., Freeman, S., Brodland, D.G., Zitelli, J. (2012). Mohs Micrographic Surgery for the Treatment of Cutaneous Melanoma. In: Nouri, K. (eds) Mohs Micrographic Surgery. Springer, London. https://doi.org/10.1007/978-1-4471-2152-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2152-7_18

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2151-0

  • Online ISBN: 978-1-4471-2152-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation